Supplementary Table 3. Multi-marker panels from previous studies

Study	Multi-marker panel	Sensitivity (%)	Specificity (%)	Comparison
Chang, 2009 [12]	CA19-9, OPN, CHI3L1	93.0		In stage II/III patients
Brand, 2011 [13]	CA19-9, ICAM-1, OPG	78.0	94.0	Discrimination from the normal
Nolen, 2014 [14]	CA19-9, CEA, Cyfra 21-1	30.4	95.0	Significantly improved performance over CA19-9
Gu, 2015 [23]	CA19-9, CA 242, CA 125, CEA	90.4	93.8	Discrimination from the normal
Park, 2018 [19]	CA19-9, LRG1, TTR	82.5	92.1	Discrimination from the normal
Mellby, 2018 [20]	IMMray PanCan-d microarray[a]	95.0	94.0	Normal *vs.* stage I/II

LRG1, leucine-rich alpha 2 glycoprotein; TTR, transthyretin.
[a]Immunovia, Lund, Sweden.